Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Gastrointestinal Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma 1Advanced Hepatocellular Carcinoma 1

Interventions

Fluorouracil 98Oxaliplatin 94Leucovorin 86Irinotecan 70Gemcitabine 66Bevacizumab 62Capecitabine 60Cetuximab 42pembrolizumab 37Cisplatin 30Nivolumab 25Drug Therapy 25130-nm albumin-bound paclitaxel 22Specimen Handling 20Folfox protocol 20Panitumumab 19Paclitaxel 19Magnetic Resonance Spectroscopy 18Albumin-Bound Paclitaxel 17Biopsy 16IFL protocol 15Floxuridine 15Docetaxel 15Cyclophosphamide 15Sorafenib 14regorafenib 12Erlotinib Hydrochloride 12aflibercept 11Radiofrequency Ablation 11fludarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × trebananib × Gastrointestinal × Clear all
NCT00752570 2015-09-02

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Amgen

Phase 2 Completed
144 enrolled
Gastrointestinal

Carcinoma, Colonic Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡